Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1766814

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1766814

China Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

PUBLISHED:
PAGES: 152 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4995
PDF (Site License)
USD 9990
PDF (Global License)
USD 14985

Add to Cart

GlobalData's "China Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the China Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The China Oncology Market report provides key information and data on -

  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
  • 2024 company share data for Oncology Market.
  • Global corporate-level profiles of key companies operating within the China Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

China Oncology is segmented as follows -

  • Colorectal Cancer Screening Tests
  • EGFR Tests
  • KRAS Tests
  • HER2 Tests
  • BRCA Tests
  • ALK Tests
  • BRAF Tests
  • BCR-ABL Tests
  • PD-L1 Tests

Reasons to Buy

The China Oncology Market report helps you to develop -

  • Business strategies by identifying the key market segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.
Product Code: GDME25617CCDB

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 What Is This Report About?
  • 2.2 Oncology Market Segmentation
  • 2.3 Definitions of Markets Covered in the Report

3 Oncology Market, China

  • 3.1 Oncology Market, China, Revenue ($m), 2018-2033
    • 3.1.1 ALK Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.2 BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.3 BRAF Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.4 BRCA Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.5 Colorectal Cancer Screening Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.6 EGFR Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.7 HER2 Tests Market, China, Revenue ($m), by Segment, 2018-2033
    • 3.1.8 KRAS Tests Market, China, Revenue ($m), by Segment, 2018-2033
  • 3.2 Oncology Market, China, Volume (Units), 2018-2033
    • 3.2.1 ALK Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.2 BCR-ABL Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.3 BRAF Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.4 BRCA Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.5 Colorectal Cancer Screening Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.6 EGFR Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.7 HER2 Tests Market, China, Volume (Units), by Segment, 2018-2033
    • 3.2.8 KRAS Tests Market, China, Volume (Units), by Segment, 2018-2033
  • 3.3 Oncology Market, China, Average Price ($) , 2018-2033
  • 3.4 Oncology Market, China, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in China, Oncology Market

  • 4.1 F. Hoffmann-La Roche Ltd
    • 4.1.1 Company Overview
  • 4.2 BioGenex Laboratories Inc
    • 4.2.1 Company Overview
  • 4.3 Amoy Diagnostics Co Ltd
    • 4.3.1 Company Overview
  • 4.4 Abbott Laboratories
    • 4.4.1 Company Overview
  • 4.5 Danaher Corp
    • 4.5.1 Company Overview
  • 4.6 Eiken Chemical Co Ltd
    • 4.6.1 Company Overview
  • 4.7 Agilent Technologies Inc
    • 4.7.1 Company Overview
  • 4.8 Hemosure Inc
    • 4.8.1 Company Overview
  • 4.9 Alfresa Pharma Corp
    • 4.9.1 Company Overview
  • 4.10 SENTINEL CH SpA
    • 4.10.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

  • 6.1 Equity Offerings
    • 6.1.1 Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares
    • 6.1.2 Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares
  • 6.2 Partnerships
    • 6.2.1 Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment
  • 6.3 Venture Financing
    • 6.3.1 Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding
    • 6.3.2 Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing
    • 6.3.3 Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing
    • 6.3.4 Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing

7 Recent Developments

  • 7.1 Other Significant Developments
    • 7.1.1 Mar 03, 2025: TruScreen - Key Markets Update and Revenue Guidance
    • 7.1.2 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
  • 7.2 Product News
    • 7.2.1 May 29, 2025: Concord Healthcare Announces Official Release of the Proton Therapy Large Model
    • 7.2.2 Apr 27, 2025: The Group's Early Detection Product for Urinary System Tumors Achieves Its First Commercial Prescription in Mainland China
    • 7.2.3 Feb 16, 2025: HKU Team Develops AI-Driven Tool to Accelerate Cancer Diagnosis
    • 7.2.4 Feb 14, 2025: New Patent Approval in China Strengthens the AroCell Patent Portfolio
    • 7.2.5 Jan 15, 2025: CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology
    • 7.2.6 Nov 11, 2024: Report Published by Research Journal, Germany's Springer Concluded that TruScreen Cervical Cancer Screening Results were Comparable and Better than conventional LBC
    • 7.2.7 Sep 20, 2024: Researchers Use Cholesterol-Enriched Exosomes to Improve Sirna Delivery
    • 7.2.8 Sep 16, 2024: Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
    • 7.2.9 Aug 23, 2024: Breakthroughs in Prostate Cancer: New Insights into Biomarkers and Probes
  • 7.3 Strategy And Business Planning
    • 7.3.1 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
    • 7.3.2 Jul 11, 2024: MGI Announces Collaboration With Predica Diagnostics
    • 7.3.3 Jun 28, 2024: Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China

8 Appendix

  • 8.1 Research Methodology
    • 8.1.1 Coverage
    • 8.1.2 Secondary Research
    • 8.1.3 Primary Research
    • 8.1.4 Market Modeling and Forecasting
    • 8.1.5 Company Share Analysis
    • 8.1.6 Benchmarking
  • 8.2 GlobalData Consulting
  • 8.3 Contact Us
  • 8.4 Disclaimer
Product Code: GDME25617CCDB

List of Table

List of Tables

  • Table 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Table 10: Oncology Market, China, Volume (Units), 2018-2033
  • Table 11: ALK Tests Market, China, Volume (Units), 2018-2033
  • Table 12: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Volume (Units), 2018-2033
  • Table 13: BRAF Tests Market, China, Volume (Units), 2018-2033
  • Table 14: BRCA Tests Market, China, Volume (Units), 2018-2033
  • Table 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033
  • Table 16: EGFR Tests Market, China, Volume (Units), 2018-2033
  • Table 17: HER2 Tests Market, China, Volume (Units), 2018-2033
  • Table 18: KRAS Tests Market, China, Volume (Units), 2018-2033
  • Table 19: Oncology Market, China, Average Price ($), 2018-2033
  • Table 19: Oncology Market, China, Company Share by Revenue ($m), 2024
  • Table 20: Oncology Market Pipeline Products
  • Table 21: Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares
  • Table 22: Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares
  • Table 23: Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment
  • Table 24: Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding
  • Table 25: Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing
  • Table 26: Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing
  • Table 27: Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing
  • Table 28: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

  • Figure 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033
  • Figure 10: Oncology Market, China, Volume (Units), 2018-2033
  • Figure 11: ALK Tests Market, China, Volume (Units), 2018-2033
  • Figure 12: BCR-ABL Tests Market, China, Volume (Units), 2018-2033
  • Figure 13: BRAF Tests Market, China, Volume (Units), 2018-2033
  • Figure 14: BRCA Tests Market, China, Volume (Units), 2018-2033
  • Figure 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033
  • Figure 16: EGFR Tests Market, China, Volume (Units), 2018-2033
  • Figure 17: HER2 Tests Market, China, Volume (Units), 2018-2033
  • Figure 18: KRAS Tests Market, China, Volume (Units), 2018-2033
  • Figure 19: Oncology Market, China, Company Share (%), 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!